Precision Neuroscience’s brain-computer interface—a wireless device that aims to restore function to people with paralysis—is ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

In response to the stronger-than-expected quarter, GE HealthCare adjusted its 2025 earnings per share profit forecast to ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Matt Adams has become the new chief executive at BrainScope, taking over from Laurie Silver, who becomes the medical ...